Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toxicokinetics/toxicodynamic correlations: goals, methods, and limitations

V K Batra1

  • 1Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, USA.

Toxicologic Pathology
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A review of recent experiments on step-to-step "hand-off" of the DNA intermediates in mammalian base excision repair pathways.

Molekuliarnaia biologiia·2011
Same author

A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma.

The Journal of pharmacology and experimental therapeutics·2005
Same author

In vitro microtuberization in potato (Solanum tuberosum L.) cultivars.

Indian journal of experimental biology·2004
Same author

Disposition and pharmacokinetics of temozolomide in rat.

Xenobiotica; the fate of foreign compounds in biological systems·2004
Same author

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe.

Clinical therapeutics·2001
Same author

Population pharmacokinetics of temozolomide in cancer patients.

Pharmaceutical research·2001

Toxicokinetic (TK) studies link drug exposure and toxicity. TK/toxicodynamic (TD) correlations enhance drug development by comparing animal and human data, especially for anticancer drugs, but require case-by-case evaluation.

Area of Science:

  • Pharmacology
  • Toxicology
  • Drug Development

Background:

  • Toxicokinetic (TK) studies establish dose-related drug exposure in preclinical models.
  • TK studies ensure animal exposure exceeds projected human therapeutic exposure.
  • Correlating TK parameters with toxicologic endpoints enhances study utility.

Purpose of the Study:

  • To explore the utility of TK/toxicodynamic (TD) correlations in drug development.
  • To discuss the application and limitations of TK/TD correlations across species.
  • To highlight the potential of TK/TD correlations in clinical trial design.

Main Methods:

  • Review of existing literature on TK and TK/TD correlations.
  • Analysis of the application of TK/TD correlations in various therapeutic areas.

Related Experiment Videos

  • Case study examples, particularly with anticancer drugs.

    • Main Results:

    • TK/TD correlations effectively bridge interspecies data and inform Phase I clinical trials.
    • These correlations are particularly valuable for anticancer drug dose escalation.
    • The assumption of comparable toxicologic responses across species at equivalent concentrations is drug-dependent.

    Conclusions:

    • TK/TD correlations offer significant benefits for drug development when applied judiciously.
    • A case-by-case approach is essential for developing and utilizing TK/TD correlations.
    • Wider adoption of TK/TD correlations beyond oncology could optimize drug development strategies.